Over the last few years, the development of genome editing has revolutionized research on the human genome. Recent advances in developing programmable nucleases, such as meganucleases, ZFNs, TALENs and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas, has greatly expedited the progress of gene editing from concept to clinical practice. The CRISPR has advantages over other nuclease-based genome editing tools due to its high accuracy, efficiency, and strong specificity. Eight years after CRISPR application for human genome edition by Emmanuelle Charpentier and Jennifer A. Doudna, the 2020 Nobel Prize in Chemistry has been jointly given to them for development of CRISPR-Cas9 gene editing, allows scientists to precisely cut and edit of DNA.
展开▼
机译：在过去几年中，基因组编辑的发展已经彻底改变了人类基因组的研究。开发可编程核酸酶的最新进展，例如Meganuclase，ZFN，Talens和聚类定期间隙的短语重复（CRISPR）/ CAS，非常加快从概念到临床实践的基因编辑的进展。由于其高精度，效率和强大的特异性，CASPR在其他基于核酸酶的基因组编辑工具中具有优势。 Emmanuelle Charpentier和Jennifer A. Doudna申请人类基因组Edition 00年八年后，2020年诺贝尔化学奖化学奖已共同向他们开发CRISPR-CAS9基因编辑，使科学家能够精确地切割和编辑DNA。
展开▼
